Compare Abbott Laboratories (ABT) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Roblox Corp — how do they compare? Abbott Laboratories trades at $110.97 (market cap $187.95B), while Roblox Corp trades at $35.6 (market cap $25.87B). The key difference: Abbott Laboratories is far larger — about 7.3× Roblox Corp's market cap, and Abbott Laboratories pays a 2.32% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| ABT | RBLX | |
|---|---|---|
Market Cap | $187.95B | $25.87B |
Sector | Health | Media |
52-Week High | $136.62 | $141.56 |
52-Week Low | $82.57 | $35.60 |
Enterprise Value | $214.96B | $24.70B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
RBLX trades at $35.76, down 3.48% in the last session, with a bearish technical outlook from moving averages. The company reported revenue growth to $4.89 billion in 2025 but remains unprofitable, with a net loss of $1.07 billion. Analyst consensus is mixed, with a $45.67 price target, while recent news highlights multiple class-action lawsuits filed against the company.
The outlook is clouded by persistent losses and legal challenges, though revenue growth and strong operating cash flow of $1.80 billion offer some fundamental support. Risks include profitability challenges and litigation, but the stock may appeal to growth-oriented investors if execution improves and losses narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
